Theravance Biopharma Inc. (NASDAQ:TBPH) has been assigned an average rating of “Buy” from the six ratings firms that are presently covering the firm. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $38.25.
TBPH has been the subject of a number of recent research reports. Bank of America Corp. downgraded Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 3rd. Leerink Swann boosted their target price on Theravance Biopharma to $29.00 and gave the stock an “outperform” rating in a research report on Monday, June 20th. Zacks Investment Research downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. Guggenheim restated a “positive” rating and issued a $40.00 target price on shares of Theravance Biopharma in a research report on Monday, September 19th. Finally, Evercore ISI initiated coverage on Theravance Biopharma in a research report on Monday, August 29th. They issued a “buy” rating and a $41.00 target price for the company.
In other Theravance Biopharma news, SVP Brett K. Haumann sold 9,509 shares of Theravance Biopharma stock in a transaction that occurred on Friday, August 19th. The stock was sold at an average price of $27.97, for a total value of $265,966.73. Following the transaction, the senior vice president now directly owns 197,391 shares of the company’s stock, valued at approximately $5,521,026.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brett K. Haumann sold 4,491 shares of Theravance Biopharma stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $27.99, for a total value of $125,703.09. Following the completion of the transaction, the senior vice president now directly owns 188,293 shares in the company, valued at $5,270,321.07. The disclosure for this sale can be found here. 4.70% of the stock is owned by company insiders.
A number of institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA boosted its position in Theravance Biopharma by 110.2% in the third quarter. BNP Paribas Arbitrage SA now owns 3,008 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,577 shares during the period. Teacher Retirement System of Texas boosted its position in Theravance Biopharma by 40.2% in the second quarter. Teacher Retirement System of Texas now owns 4,887 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 1,401 shares during the period. PNC Financial Services Group Inc. boosted its position in Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 192 shares during the period. Bellevue Group AG acquired a new position in Theravance Biopharma during the first quarter valued at about $215,000. Finally, Paloma Partners Management Co acquired a new position in Theravance Biopharma during the second quarter valued at about $255,000. 69.89% of the stock is currently owned by institutional investors and hedge funds.
Theravance Biopharma (NASDAQ:TBPH) opened at 36.73 on Monday. The firm’s 50 day moving average price is $32.29 and its 200-day moving average price is $24.81. Theravance Biopharma has a 12-month low of $12.75 and a 12-month high of $37.46. The company’s market capitalization is $1.76 billion.
Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.01. Theravance Biopharma had a negative return on equity of 70.79% and a negative net margin of 471.82%. On average, equities analysts anticipate that Theravance Biopharma will post ($4.03) earnings per share for the current fiscal year.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.